Serum selenium and subsequent risk of prostate cancer.
It is suspected that selenium is protective against prostate cancer. To test this hypothesis, we conducted a nested case-control study in a cohort of 9345 Japanese-American men examined between 1971 and 1977. At the time of examination, a blood specimen was obtained, and the serum was frozen. After a surveillance period of more than 20 years, 249 tissue-confirmed incident cases of prostate cancer were identified. Their stored sera and those of 249 matched controls were measured for selenium levels. Odds ratios for prostate cancer, based on quartiles of serum selenium levels, were determined using the General Estimating Equations approach. The multivariate odds ratio for the highest quartile was 0.5 (95% confidence interval, 0.3-0.9) with a two-sided P for trend of 0.02. The inverse association was more notable for cases with advanced disease and for cases diagnosed 5-15 years after phlebotomy. However, the association was mainly present in current or past cigarette smokers rather than nonsmokers, which leads to caution in the interpretation of the results.
Nomura
A M
AM
Japan-Hawaii Cancer Study, Kuakini Medical Center, Honolulu 96817, USA.
Lee
J
J
Stemmermann
G N
GN
Combs
G F
GF
D000368:Aged; D016022:Case-Control Studies; D006254:Hawaii / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011471:Prostatic Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000209:etiology; D012307:Risk Factors; D012643:Selenium / Q000097:blood*; D012907:Smoking / Q000009:adverse effects / Q000097:blood
D012643:Selenium